Marijuana Could Fight Or Potentially Cure These 5 Diseases

The costs to treat schizophrenia range from $32.5 billion to $65 billion annually.  In 2012, a study published in Translational Psychiatry hinted that cannabinoid CBD may prove to be an attractive substitute for current antipsychotic treatments. In total, the study examined 39 patients, dosing 20 with CBD and 19 with amisulpride.

While both led to similar Brief Psychiatric Rating Scale scores upon study completion, it was noted that the CBD group had fewer side effects than the amisulpride group. Keep in mind that THC, not CBD, is the hallucinogenic component of marijuana. As should be no surprise by now, GW Pharma is also developing GWP42003 as a potential treatment for schizophrenia.

To read more, visit

Posted in: Investing

Comments are closed.